On April 5th, Trinity Partner Herman Sanchez will speak on a panel at the second annual Pharmacy Industry Summit, organized by Mintz Levin, discussing the current drug pricing debate and the evolving roles of pharmacy industry players. The conference brings together stakeholders and thought leaders from across the country to discuss legal and policy challenges facing manufacturers, PBMs, payers, pharmacies and providers. View the agenda here: http://bit.ly/2nBffiA
The conference brings together Latino and Latina High School students in San Luis Obispo County, motivating them to aim for success in college, helping them to identify career goals and coaching them on how to achieve their goals. Learn more about the inspiring event: http://bit.ly/2nibqyM
Trinity Partners, a leading global life sciences consulting firm, had several company experts attend the 2017 AMCP Managed Care & Specialty Pharmacy Annual Meeting from March 27-30 in Denver, Colorado.
Trinity employees presented two posters at the annual meeting. The first, titled, “Determining the Cost of Care for Spinal Muscular Atrophy (SMA) using Retrospective Claims Analysis,” was created by several Trinity employees in association with Biogen to help support the highly-anticipated launch of Spinraza. The second poster, titled, “Utilization of Geriatric Care among Medicare Beneficiaries” was developed with the help of Trinity’s statistics team.
The AMCP Managed Care & Specialty Pharmacy Annual Meeting is designed to bring together managed care pharmacists, health plan administrators, medical directors, formulary decision-makers and other industry leaders to discuss breakthrough drug therapies, updates in legislation and regulation, research and formulary management.
Learn more about the conference here: http://bit.ly/1H4ZuUK
He asserts that the first product to offer patients the ability to self-administer at home could drive separation from the pack. Read more: http://bit.ly/2nBn2Bm
Trinity Partners has appointed Kevin Francis to director of analytics & insights, and Alex Chiang will serve as principal. Both employees have experienced continued growth with the firm, with a tenure of almost twelve and ten years respectively.
In his new role, Kevin will be responsible for leading a team of analytics professionals that focus on leveraging secondary data to drive actionable insights for pharmaceutical and biotechnology clients. He will continue leading the firm’s charge on large-scale data integration engagements involving patient claims and transactional sales data. Kevin will also partner with the strategy consulting team to integrate secondary data into their projects.
Kevin graduated from Bentley University with an Economics degree. He has contributed analyses for several publications, including the Journal of Medical Economics and the Journal of Clinical Epidemiology. Kevin’s work has also been presented at conferences and events, including the Academy of Managed Care Pharmacy Annual Meeting, the ASH Annual Meeting and the ISPOR Annual Meeting. He has been with Trinity for more than eleven years and most recently served as engagement manager, advanced analytics.
“Kevin possesses a deep understanding of secondary data, and has leveraged that knowledge to drive actionable insights for clients.” said Dave Fitzhenry, managing partner, Trinity Partners. “Further, as he has transitioned into a leadership role, he has developed innovative processes to help refine Trinity’s data management and analytics capabilities. Not only do clients clamor to work with him, colleagues rely on Kevin and his team for quick turnaround help on important projects.”
Alex, who has been with Trinity since 2007, will continue advising life sciences clients on a range of therapeutic areas, including oncology and specialty diseases. He has had significant exposure across Trinity’s strategic offerings and practice areas, including forecasting, advanced analytics, corporate strategy, and primary market research. Alex will also continue to lead Trinity’s New York City office.
Alex received an Economics degree and a certificate in American Studies from Princeton University and an MBA from Columbia. His analysis on personalized medicine in oncology was published in Nature Reviews Drug Discovery.
“Alex is a natural leader and mentor to many Trinity employees. Accordingly, he quickly rose through the ranks from associate to engagement manager and now principal,” said Fitzhenry. “Alex has also demonstrated a knack for partnering with clients to help them maximize current assets and develop a roadmap to success across therapeutic areas.”
These promotions are an indication of Trinity’s ongoing growth. Based just outside of Boston, the company has additional offices in San Francisco, Princeton and New York City. Throughout Trinity’s twenty plus years in business, the company has prioritized investments in employee growth and development with management programs, career skills training and mentorship programs.
Just as Kevin and Alex took advantage of the career growth opportunities offered to them throughout their lengthy careers with the firm, they now serve as mentors to junior staff, and will continue to take on employee development roles in addition to their regular responsibilities.
Trinity Partners honored Rare Disease Day on February 28th, a day dedicated to raising awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives. We attended several events throughout the country, including MassBio’s Patient Advocacy meeting at the Massachusetts State House and the Metropolitan Hospital Center’s Rare Disease event in New York City. We also tuned into MassBio and ABC News’ Rare Disease Day Tweetchat. Check out a few pictures of our team advocating for the rare disease community!
Global life sciences consulting firm Trinity Partners today announced that a few of its experts will share insights at the CBI Reimbursement and Contracting Conference, being held in Philadelphia, PA from February 28 – March 1, 2017. Their presentation, titled, ‘Garner Insight on Key Changes to Medical Benefit Reimbursement and Implications for Drug Contracting and Pricing’ will take place today at 2:00 p.m. EST. Also in attendance will be Partner Herman Sanchez.
“There have been significant market changes in this space even since Trinity Partners last presented to this audience at the 2015 conference,” said Sanchez. “We look forward to discussing these important evolutions.”
During this year’s presentation, Engagement Manager John Greenaway and Senior Consultant Nicholas Simmons-Stern will address Medicare Part B changes and their impact on the reimbursement and the contracting landscape. The two will take a deep dive into the oncology care model and discuss the evolving buy-and-bill landscape through case study examples, and will also explore how to overcome reimbursement hurdles in the expanding U.S. biosimilars market.
The presentation will include the following:
- Assessment of the current US biosimilar landscape including pathways to approval and market trends
- Discussions around the latest regulatory updates and FDA guidance on labeling for biosimilar products and interchangeability to determine impact on launch price and contracting strategies
- Insights into the Healthcare Common Procedure System (HCPCS) J Codes billing system
“The healthcare landscape is evolving rapidly and pricing pressures are continuing to mount,” said Greenaway. “It is rewarding to be able to share insights and discuss these important shifts with market leaders in the hopes of helping bio/pharmaceutical companies prepare for long-term success.”
Now in its fourth year, CBI’s Reimbursement and Contracting conference provides a platform for bio/pharmaceutical manufacturers looking to unravel complexities associated with reimbursement, pricing strategies and commercial contracting.
Our NYC team will be attending the Metropolitan Hospital Center’s Rare Disease Day event. Learn more and register for an exciting afternoon with physicians, patients, and caregivers dedicated to rare disease awareness. http://bit.ly/2l2B4K3
Ahead of Rare Disease Day next Tuesday, we’ll be raising awareness for the day and the community across all of our social channels this week. Check back in to learn more about this unique community!
What qualifies as a rare disease? Any disease, disorder, illness or condition affecting fewer than 200,000 people in the US is considered rare. 7,000 rare diseases exist and only 5% have FDA-approved treatments. Learn more: http://bit.ly/RDDFacts
Principal Jillian Godfrey Scaife recently spoke with Specialty Pharmacy Times about the impact that the FDA’s recent biosimilar interchangeability draft guidance will have on specialty pharmacy. Read the Q&A here: http://bit.ly/2jZdudr